HDAC9 and neoplasm: Entinostat is a more selective, class I-specific HDAC inhibitor that has been shown to induce apoptotic effects and cell cycle arrest in lymphoma cells (24), reduce tumor growth, and improve antigen-presentation in ovarian cancer models (25).